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CASE REPORT / OLGU SUNUMU
Approach to hypersplenism due to splenic metastasis of breast cancer: A case report
Meme kanseri dalak metastazına bağlı gelişen hipersplenizme yaklaşım: Olgu sunumu
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ÖZET
Meme kanserinin en sık metastaz bölgeleri kemikler, ak-
ciğerler, karaciğer, lenf nodları ve beyindir. Meme kanse-
rinin  dalağa  metastazı  ise  çok  nadirdir.  Hipersplenizm, 
karsinomalarda ciddi hemolitik aneminin bir nedeni olarak 
veya dalak metastazına bağlı aşırı dalak büyümesiyle or-
taya çıkar. Hipersplenizme bağlı pansitopeninin tedavisin-
de splenektomi yararlı olabilmektedir. Biz hipersplenizm 
ile ilişkili sitopeniyi düzeltmek için splenektomi yapılan da-
lak metastazlı nadir bir meme kanseri olgusunu sunduk. 
Bu olgunun ışığında metastatik kanserli hastalarda dalak 
metastazına bağlı oluşan hipersplenizm tedavisinde sple-
nektomi faydalı olabilmektedir.
Anahtar kelimeler: Meme kanseri, hipersplenizm, sple-
nektomi.
ABSTRACT
The  most  common  sites  for  breast  cancer  metastasis 
include the bones, lungs, liver, lymph nodes, and brain. 
However,  splenic  metastasis  of  breast  cancer  is  ex-
tremely rare. Hypersplenism occurs as a cause of severe 
hemolytic anemia in carcinomas or with marked splenic 
enlargement related to splenic metastasis. We presented 
a rare case of breast cancer with splenic metastasis that 
was undergone splenectomy to correct cytopenia related 
to hypersplenism. In the light of this case, splenectomy 
can be beneficial in the patients with hypersplenism.
Key words: Breast cancer, hypersplenism, splenectomy.
INTRODUCTION
Metastatic tumors of the spleen are rare and usually 
occur in the presence of disseminated visceral me-
tastases. The most common tumors causing splenic 
metastases are breast, lung, colorectal, and ovarian 
carcinoma  and  melanoma.1  Hypersplenism  repre-
sents the increased pooling and/or destruction of the 
corpuscular elements of the blood by the enlarged 
spleen. Hypersplenism is a condition which cytope-
nia develop due to splenomegaly and may be sus-
pected as a cause of severe hemolytic anemia in ad-
vanced neoplasms.2 Splenectomy can be performed 
as palliation with acceptable morbidity in patients 
with  symptomatic  splenomegaly  to  improve  the 
quality of life.1 In cases of isolated splenic metas-
tasis, especially in colon and breast cancer, splenec-
tomy is beneficial because it has a low complication 
rate and potential long term survival is higher.2,3 In 
the literature, hypersplenism due to splenic metas-
tasis of breast cancer is very rare. We report herein 
a rare case of a splenic metastasis due to breast can-
cer in a young patient who underwent splenectomy 
for the correction of cytopenia as a cause of hyper-
splenism.M. Küçüköner, et al. Approach to hypersplenism 118
Dicle Tıp Derg / Dicle Med J    www.diclemedj.org   Cilt / Vol 39, No 1, 117-120
CASE REPORT
A 33-year old premenopausal patient presented with 
left breast mass. She was diagnosed with invasive 
ductal carcinoma by biopsy. On the first examina-
tion of the patient, ECOG performance score was 
1 and breast examination revealed an 8×4 cm mass 
in the left breast. Abdominal examination revealed 
hepatomegaly.  Other  system  examinations  were 
normal. Hematological analysis was normal except 
anemia (hemoglobin: 10g/dl). Biochemical parame-
ters including liver function tests and renal function 
tests were within normal limits.
Computed  tomography  of  the  abdomen  and 
thorax revealed multiple hipodens lesions in the liv-
er and a mass in the left breast. Additionally, bone 
sintigraphy of the patient presented bone metasta-
sis. In these images, the spleen size was in normal 
range. The clinical and radiological TNM staging 
was T4N2M1. The pathological biopsy revealed es-
trogen and progesterone receptor (+), and cERB2 
(-).  Palliative  chemotherapy  was  administered; 
three cycles of cyclophosphamide, doxorubicin, and 
bisphosphonate. Three months after the chemoth-
eraphy, thrombocytopenia (platelet range: 60.000-
80.000) occurred. Since the platelet counts had not 
increased, bone marrow biopsy was performed. The 
bone marrow biopsy documented an increased cel-
lularity and carcinoma infiltration. Although there 
was  a  thrombocytopenia,  chemotherapy  (weekly 
paclitaxel and capesitabine) was administered due 
to the disease progression.
Because  of  thrombocytopenia  of  the  patient, 
lower doses of myelosupressive adverse chemother-
apeutics were administered as monotherapy. Firstly, 
paclitaxel was given to the patient every week dur-
ing  6  months.  When  chemotherapy  response  de-
creased, oral capesitabine was administered nearly 
for 6 months. The disease was stable as clinically 
and radiologically nearly 16 months from the di-
agnosis. The patient exhibited a partial response to 
chemotherapy for nearly 16 months. In the course of 
this time, platelet count range was 20.000-60.000. 
Due to decrease platelet counts below 20.000, and 
gingival bleeding and conjunctival hemorrhage, the 
patient  was  hospitalized. Abdominal  examination 
revealed  hepatomegaly  and  a  new  occurrence  of 
splenomegaly.
In  the  computary  tomography,  multiple  me-
tastasis and organomegali presented in the spleen 
and liver (Figure 1). The laboratory results were as 
follows; hemogram: White blood cell: 2940 K/UL, 
Neutrophil: 1620K/UL, Hemoglobin:8 gr/dl, Hema-
tocrit:%24, and Platelets:17200K/UL. Additionally, 
the blood biochemical analysis was normal. Direct 
and indirect Coombs tests were negative. Although 
the patient was given steroid and medical therapy, 
platelet level was continued as 5.000-20.000. Be-
cause of the gingival and conjunctival bleeding due 
to thrombocytopenia, the patient was given frequent 
thrombocyte and erythrocyte transfusions once in 
two days for a month.
Figure 1.  Multiple  metastasis  and  organomegali 
presented in the spleen and liver In the computed 
tomography
Pancytopenia  related  to  hypersplenism  was 
considered because of the increased cellularity doc-
umented in bone marrow biopsy, and splenomegaly 
demonstrated  in  the  ultrasonography. The  patient 
was consulted to surgery for splenectomy because 
of  thrombocyte  was  not  improved  with  medical 
therapy. After preoperative preparation of the pa-
tient  with  platelet  transfusions,  splenectomy  was 
performed. Two days after splenectomy, the platelet 
level of the patient increased to 182.000. Adenocar-
cinoma metastasis was reported after splenectomy 
material had been evaluated. The diagnosis report 
was as follows; Malignant Epithelial Tumor infiltra-
tion in a desmoplastic stroma in the spleen (Figure2, 
3 H&EstainX100). In the examination of immuno-
histochemical, cERB2 was negative. After the sple-
nectomy, the patient has been followed up with nor-
mal platelet level for nearly 9 months. Afterwards, M. Küçüköner, et al. Approach to hypersplenism 119
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palliative chemotherapy was applied to the patient 
again. The disease of breast cancer of the patient has 
continued without any progression. Platelet count 
was 122.000 K/UL during the last chemotherapy. 
However, myelosuppresion and hepatic toxicity de-
veloped after chemotherapy and unfortunately the 
patient passed away.
Figure 2. Malignant Epithelial Tumor infiltration in a 
desmoplastic stroma in the spleen. (H&EstainX100).
Figure 3. A parenchymal area adjacent to the tumor 
cells in the spleen. (H&EstainX100).
DISCUSSION
Metastatic tumors of the spleen are rare and usu-
ally occur in the presence of disseminated viscer-
al metastases at terminal stage. The prevalence of 
splenic metastases in large populations with cancer 
was  mainly  obtained  from  autopsy  series  ranged 
between 2.3% and 7.1%.4 In a Japanese study, in 
0.15% of the patients, splenic metastasis was de-
tected by ultrasonography.5 The rarity of splenic 
metastases could be explained by anatomic factors 
and the inhibitory effect of the splenic microenvi-
ronment on the growth of metastatic cells. Several 
theories have been showed efforts to the resistance 
of spleen parenchyma against metastases. Some of 
these include the ability of the splenic capsule to 
form a physical barrier, angled and a corrugated an-
atomic feature of splenic artery and immunological 
defense of the spleen against neoplastic cells.6
Hypersplenism represents the increased pool-
ing and/or destruction of the corpuscular elements 
of the blood by the enlarged spleen. Hypersplenism 
may be suspected as a cause of severe hemolytic 
anemia  in  advanced  carcinoma.  Hypersplenism 
was  diagnosed  in  connection  with  splenomegaly, 
pancytopenia and increased cellularity documented 
in bone marrow biopsy. Immune mechanisms and 
splenomegaly are responsible for hypersplenism.7,8 
For these reasons, our patient was given steroid and 
medical therapy. Since the response had not been 
achieved for the medical therapy, due to low throm-
bocyte  count,  splenectomy  was  performed. After 
splenectomy, the patient has been followed up with 
normal platelet level for nearly 9 months. The dis-
ease of breast cancer of the patient has continued 
without  progression  during  these  nine  months  of 
period. At the tenth months, the patient passed away 
because of the toxicity of chemotherapy in the 10th 
months.
In the literature, two cases have been reported 
that hypersplenism was corrected with splenectomy 
in  patients  with  advanced  breast  cancer  who  did 
not response to medical therapy. Additionally, sple-
nectomy which was performed to the patient with 
isolated  splenic  metastasis  has  improved  overall 
survival. Splenic metastasis in ovarian carcinomas 
has been reported in the literature and splenectomy 
has been shown to be beneficial for these patients. 
Splenectomy is meaningful to the isolated spleen 
metastasis of the carcinomas. In the literature, it was 
reported that splenectomy was beneficial for the pa-
tients with over, colon and breast cancer with the 
spleen metastasis.2,9 Moreover, splenectomy can be 
performed with palliative purposes in patients with 
acceptable morbidity and symptomatic splenomeg-
aly (cytopenia with hypersplenism).1M. Küçüköner, et al. Approach to hypersplenism 120
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We presented a rare case of breast cancer with 
splenic metastasis who underwent splenectomy to 
correct cytopenia related with hypersplenism. Addi-
tionally, in the lights of these cases with hypersplen-
ism in the literature, splenectomy may be beneficial 
in patients with hipersplenism.
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